Radiolabeled anti-lymphoma antibodies.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This promises to be an era of remarkable change for patients afflicted with NHL. Although the cause of NHL remains unknown, there is greater understanding of 'these diseases' at the molecular level. Insights into genetic aberrations that interrupt apoptosis or that promote proliferation have profound implications for the future management of NHL (and other malignancies). Ongoing trials of immunotherapy and RIT continue to show excellent response rates in patients with relapsed or refractory NHL and remarkably favorable safety and toxicity profiles. More drug approvals can be anticipated. As antibody engineering progresses, formerly theoretical questions regarding optimized targeting and antibody affinity, take on relevance and practicality [65]. The ability to generate new constructs, such as bivalent antibodies, or fusion proteins incorporating two disparate functional proteins, presents exciting opportunities for radiopharmaceutical development. The role of bifunctional antibodies in tumor targeting is likely to increase in importance, both as a means of targeting, and as a technique for increasing MAb specificity [66,67]. Pretargeting approaches are in development as a way of decreasing the amount of time that the radionuclide circulates in the blood (radiating normal tissues) thereby allowing the administration of higher doses of radionuclide (radioactivity and radiation) [67-69].

Original languageEnglish (US)
Pages (from-to)297-308
Number of pages12
JournalCancer chemotherapy and biological response modifiers
Volume19
StatePublished - 2001

Fingerprint

Radioisotopes
Anti-Idiotypic Antibodies
Lymphoma
Bispecific Antibodies
Drug Approval
Antibody Affinity
Radiopharmaceuticals
Antibodies
Immunotherapy
Radioactivity
Neoplasms
Proteins
Radiation
Apoptosis
Safety

Cite this

Radiolabeled anti-lymphoma antibodies. / Denardo, Gerald L; O'Donnell, Robert T; DeNardo, S. J.

In: Cancer chemotherapy and biological response modifiers, Vol. 19, 2001, p. 297-308.

Research output: Contribution to journalArticle

@article{7a11e67142854faf98edf6e4cbad8d5b,
title = "Radiolabeled anti-lymphoma antibodies.",
abstract = "This promises to be an era of remarkable change for patients afflicted with NHL. Although the cause of NHL remains unknown, there is greater understanding of 'these diseases' at the molecular level. Insights into genetic aberrations that interrupt apoptosis or that promote proliferation have profound implications for the future management of NHL (and other malignancies). Ongoing trials of immunotherapy and RIT continue to show excellent response rates in patients with relapsed or refractory NHL and remarkably favorable safety and toxicity profiles. More drug approvals can be anticipated. As antibody engineering progresses, formerly theoretical questions regarding optimized targeting and antibody affinity, take on relevance and practicality [65]. The ability to generate new constructs, such as bivalent antibodies, or fusion proteins incorporating two disparate functional proteins, presents exciting opportunities for radiopharmaceutical development. The role of bifunctional antibodies in tumor targeting is likely to increase in importance, both as a means of targeting, and as a technique for increasing MAb specificity [66,67]. Pretargeting approaches are in development as a way of decreasing the amount of time that the radionuclide circulates in the blood (radiating normal tissues) thereby allowing the administration of higher doses of radionuclide (radioactivity and radiation) [67-69].",
author = "Denardo, {Gerald L} and O'Donnell, {Robert T} and DeNardo, {S. J.}",
year = "2001",
language = "English (US)",
volume = "19",
pages = "297--308",
journal = "Cancer chemotherapy and biological response modifiers",
issn = "0921-4410",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Radiolabeled anti-lymphoma antibodies.

AU - Denardo, Gerald L

AU - O'Donnell, Robert T

AU - DeNardo, S. J.

PY - 2001

Y1 - 2001

N2 - This promises to be an era of remarkable change for patients afflicted with NHL. Although the cause of NHL remains unknown, there is greater understanding of 'these diseases' at the molecular level. Insights into genetic aberrations that interrupt apoptosis or that promote proliferation have profound implications for the future management of NHL (and other malignancies). Ongoing trials of immunotherapy and RIT continue to show excellent response rates in patients with relapsed or refractory NHL and remarkably favorable safety and toxicity profiles. More drug approvals can be anticipated. As antibody engineering progresses, formerly theoretical questions regarding optimized targeting and antibody affinity, take on relevance and practicality [65]. The ability to generate new constructs, such as bivalent antibodies, or fusion proteins incorporating two disparate functional proteins, presents exciting opportunities for radiopharmaceutical development. The role of bifunctional antibodies in tumor targeting is likely to increase in importance, both as a means of targeting, and as a technique for increasing MAb specificity [66,67]. Pretargeting approaches are in development as a way of decreasing the amount of time that the radionuclide circulates in the blood (radiating normal tissues) thereby allowing the administration of higher doses of radionuclide (radioactivity and radiation) [67-69].

AB - This promises to be an era of remarkable change for patients afflicted with NHL. Although the cause of NHL remains unknown, there is greater understanding of 'these diseases' at the molecular level. Insights into genetic aberrations that interrupt apoptosis or that promote proliferation have profound implications for the future management of NHL (and other malignancies). Ongoing trials of immunotherapy and RIT continue to show excellent response rates in patients with relapsed or refractory NHL and remarkably favorable safety and toxicity profiles. More drug approvals can be anticipated. As antibody engineering progresses, formerly theoretical questions regarding optimized targeting and antibody affinity, take on relevance and practicality [65]. The ability to generate new constructs, such as bivalent antibodies, or fusion proteins incorporating two disparate functional proteins, presents exciting opportunities for radiopharmaceutical development. The role of bifunctional antibodies in tumor targeting is likely to increase in importance, both as a means of targeting, and as a technique for increasing MAb specificity [66,67]. Pretargeting approaches are in development as a way of decreasing the amount of time that the radionuclide circulates in the blood (radiating normal tissues) thereby allowing the administration of higher doses of radionuclide (radioactivity and radiation) [67-69].

UR - http://www.scopus.com/inward/record.url?scp=0035225283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035225283&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 297

EP - 308

JO - Cancer chemotherapy and biological response modifiers

JF - Cancer chemotherapy and biological response modifiers

SN - 0921-4410

ER -